C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

New live bacterial product for stubborn superbug improves quality of life Microbiome therapeutic tackles C. diff, the most common health care-associated infectious agent in the US. Date: January 31, ...

Late last year, The Jewish Hospital-Mercy Health in Cincinnati received a first-place award in a multi-state competition for its efforts to reduce Clostridium difficile infections among inpatients.

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

Please provide your email address to receive an email when new articles are posted on . Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often ...

Each year, about 500,000 people in the U.S. deal with gastrointestinal infections from Clostridioides difficile (C. diff), and more than 20,000 die from these infections. A new study performed in mice ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...